Mucolytics, expectorants, and mucokinetic medications

Respiratory Care

Volumn 52, Issue 7, 2007, Pages 859-865

  Rubin, Bruce K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Airway secretions; Cystic fibrosis; Dornase alfa; Expectorant; Mannitol; Mucin; Mucokinetic; Mucolytic; Mucus; N acetylcysteine; Surfactant; Thymosin

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; AMILORIDE; BICARBONATE; BRONCHODILATING AGENT; DENUFOSOL; DEXTRAN; DEXTROMETHORPHAN; DORNASE ALFA; ERDOSTEINE; EXPECTORANT AGENT; GELSOLIN; GUAIFENESIN; HEPARIN; IODINATED GLYCEROL; IODOPROPYLIDENE GLYCEROL; MANNITOL; METHYLXANTHINE BRONCHODILATOR; MUCIN 5AC; MUCIN 5B; MUCINEX; MUCOKINETIC AGENT; MUCOLYTIC AGENT; NACYSTELYN; POTASSIUM IODIDE; PURINERGIC RECEPTOR STIMULATING AGENT; RESPIRATORY TRACT AGENT; SODIUM CHLORIDE; SURFACTANT; THYMOSIN BETA4; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

AEROSOL; AIRWAY OBSTRUCTION; ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; BIOFILM; BRONCHIECTASIS; BRONCHITIS; BRONCHUS SECRETION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; HYPEROSMOLALITY; INFLAMMATORY CELL; MUCOCILIARY CLEARANCE; MUCUS; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT INJURY; SCANNING ELECTRON MICROSCOPY; SPUTUM VISCOSITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTICLE; CLASSIFICATION; UNITED STATES;

EXPECTORANTS; HUMANS; TREATMENT OUTCOME; UNITED STATES;

EID: 34548593997     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Rubin BK, van der Schans CP, editors. Therapy for mucus clearance disorders. Biology of the Lung Series, Claude Lenfant (NIH) Executive editor. New York: Marcel Dekker; 2004.
2. Rubin BK, Tomkiewicz RP, King M. Mucoactive agents: old and new. In: Wilmott RW, editor. The pediatric lung. Basel: Birkhäuser Publishing; 1997: 155-179.
3. Rubin BK. Surface properties of respiratory secretions: relationship to mucus transport. In: Baum G, editor. Cilia, mucus, and mucociliary clearance. New York: Marcel Dekker; 1998: 317-324.
4. Shim C, King M, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987;92(4):679-682.
5. Marchette LC, Marchette BE, Abraham WM, Wanner A. The effect of systemic hydration on normal and impaired mucociliary function. Pediatr Pulmonol 1985;1(2):107-111.
6. Jager EG. Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients. Clin Ther 1989;11(3):341-362.
7. Pavia D, Agnew JE, Glassman JM, Sutton PP, Lopez-Vidriero MT, Soyka JP, Clarke SW. Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients, Eur J Respir Dis 1985;67(3):177-184.
8. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996;109(2):348-352.
9. Rubin BK. An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol. Chest 1999; 116(1):195-200.
10. Stutts MJ, Fitz JG, Paradiso AM, Boucher RC. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am J Physiol 1994;267(5 Pt 1):C1442-C1451.
11. Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, et al; Cystic Fibrosis Therapeutics Development Research Group. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol 2001;32(2):122-128.
12. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, et al; Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis, Pediatr Pulmonol 2005;39(4):339-348.
13. Daviskas E, Anderson SD, Gomes K, Briffa P, Cochrane B, Chan HK, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirol 2005;10(1):46-56.
14. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354(3):241-250.
15. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-240.
16. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2002;(1):CD002996.
17. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-1321.
18. Tomkiewicz RP, Kishioka C, Freeman J, Rubin BK. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G, editor. Cilia, mucus and mucociliary interactions. New York: Marcel Dekker; 1998: 333-341.
19. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004;31(1):86-91.
20. King M, Rubin BK. Mucus rheology: relationship with transport. In: Takishima T, editor. Airway secretion: physiological bases for the control of mucus hypersecretion. New York: Marcel Dekker; 1994: 283-314.
21. Puchelle E, Zahm JM, Girard F, Bertrand A, Polu JM, Aug F, Sadoul P. Mucociliary transport in vivo and in vitro: relations to sputum properties in chronic bronchitis. Eur J Respir Dis 1980;61(5):254-264.
22. Rubin BK. Mucoactive agents for the treatment of cough. In: Chung F, Widdicombe J, Boushey H, editors. Cough: causes, mechanisms, and therapy. Oxford: Blackwell Publishing; 2003: 269-281.
23. Sheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964 Nov;90:721-729.
24. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994;88(7):531-535.
25. British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985;40(11):832-835.
26. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003;21(5):795-798.
27. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22(2):209-221.
28. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365(9470):1552-1560. Erratum in: Lancet 2005;366(9490):984.
29. King M, Rubin BK. Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002; 54(11):1475-1490.
30. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 2006;103(12):4628- 4633.
31. Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med 2007; 175(8)816-821.
32. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996;153(2):752-760.
33. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331(10):637-642.
34. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum., Proc Natl Acad Sci U S A 1990;87(23):9188-9192.
35. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148(1):145-151.
36. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326(12):812-815.
37. Rubin BK. Who will benefit from DNase? (editorial) Pediatr Pulmonol 1999;27(1):3-4.
38. Puchelle E, Zahm JM, de Bentzmann S, Grosskopf C, Shak S, Mougel D, Polu JM. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996;9(4):765-769.
39. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994;263(5149):969-971.
40. Rubin BK, Kater AP, Goldstein AL. Thymosin β4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006;130(5):1433-1440.
41. Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med 1998;157(3 Pt 1):710-714.
42. Isawa T, Teshima T, Hirano T, Ebina A, Konno K. Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs. Tohoku J Exp Med 1986;150(1):51-61.
43. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990;9(3):170-176.
44. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. J Appl Physiol 1985;58(6):1776-1782.
45. Finley TN, Ladman AJ. Low yield of pulmonary surfactant in cigarette smokers. N Engl J Med 1972;286(5):223-227.
46. Girod S, Galabert C, Lecuire A, Zahm JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr Pulmonol 1992;13(1):22-27.
47. Albers GM, Tomkiewicz RP, May MK, Ramirez OE, Rubin BK. Ring distraction technique for measuring surface tension of sputum: relationship to sputum clearability. J Appl Physiol 1996;81(6):2690-2695.
48. Hite RD, Seeds MC, Jacinto RB, Balasubramanian R, Waite M, Bass D. Hydrolysis of surfactant-associated phosphotidylcholine by mammalian secretory phospholipases A2. Am J Physiol 1998:275(4 Pt 1):L740-L747.
49. Okamoto K, Kim J-S. Rubin BK. Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea. Am J Physiol Lung Cell Mol Physiol 2007;292(1):L62-L67.
50. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278(17):1426-1431.
51. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis: clinical trial in 120 patients at two different doses. Respiration 1987;51 Suppl 1:37-41.
52. Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard): an open, long-term, multicenter study in 5,635 patients. Respiration 1989;55 Suppl 1:84-96.
53. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987;92(4):618-620.